Cancer type
Liver / HCC
Liver cancer and hepatocellular carcinoma.
Must-know
1
Serial ctDNA and recurrence in hepatocellular carcinoma
Zhu et al. Molecular Oncology. 2022.
In this prospective study, preoperative ctDNA and the median variant allele fraction at baseline were independent predictors of recurrence-free survival.
A randomized ctDNA-guided hepatocellular carcinoma trial was not identified.
Listed when a study is a randomized or prospective interventional ctDNA or MRD trial, is cited in NCCN or ESMO guidance, or is a prospective validation cohort in a high-impact journal. Shorter lists mean fewer studies met that rule. No test is ranked.
Trials
Recruiting · Not applicable
NCT07001085 ctDNA monitoring in hepatocellular carcinoma and metastatic colorectal cancer
Interventional study of serial ctDNA in hepatocellular carcinoma and in colorectal cancer metastatic to the liver. The registry lists the phase as not applicable and the primary outcome as assessment of the clinical value of the ctDNA level. ClinicalTrials.gov lists the study as recruiting.
No Colorectal and GI updates are on file for this filter.